479
Abstract Views
350
PDF Download
Hematology

Does platelet/ lymphocyte ratio a predictor of CD34+ peripheral blood stem cell yield in the healthy donors mobilized with GCSF?

Pages 115-120

Abstract

This research aimed to determine whether there is a correlation between platelet/lymphocyte ratio the number of collected CD34+ stem cells. This retrospective study included 94 adult related stem cell donors who were healthy and volunteer by screening their files between the years 2016 and 2018. All donors were mobilized using 2.5 mcg/kg lenograstim or filgrastim and underwent peripheral stem cell apheresis. Complete blood counts were tested at baseline before G-CSF administration (pre–G-CSF), and before PBSC collection after mobilization with G-CSF administration. The patients were divided into two groups as aged below and over 50 years old. From these comparative data, only BMI value of the group aged below 50 years was statistically significantly lower than the other group, whereas no statistically significant difference was found between the groups in terms of other parameters. The numbers of the collected CD34+ stem cells of both age groups were similar, and no significant difference was found. The values of platelet/lymphocyte ratio, early measurement of CD34+ stem cells and the amount of the collected CD34+ stem cells of both groups at the first and second days of the procedure were found similar. This research show that a high platelet count and consequently, a high platelet/lymphocyte ratio may be correlated with the number of collected CD34+ stem cells but our hypotheses revealed insignificant outcomes.

There is no Figure or data content available for this article

References

1. Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M, Urbano-Ispizua A. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant. 2005;36(7):575-590. doi:10.1038/sj.bmt.1705104
2. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers. N Engl J Med. 2001;344(3):175-181. doi:10.1056/NEJM200101183440303
3. Storb R, Prentice RL, Thomas ED. Marrow Transplantation for Treatment of Aplastic Anemia. N Engl J Med. 1977;296(2):61-66. doi:10.1056/NEJM197701132960201
4. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94(4):1465-1470. http://www.ncbi.nlm.nih.gov/pubmed/10438735.
5. Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2006;107(4):1688-1695. doi:10.1182/blood-2005-05-1897
6. Ringden O, Barrett AJ, Zhang M-J, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol. 2003;121(6):874-885. doi:10.1046/j.1365-2141.2003.04364.x
7. Melve GK, Ersvær E, Kittang AO, Bruserud Ø. The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target? Expert Rev Hematol. 2011;4(5):563-576. doi:10.1586/ehm.11.54
8. Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood. 1999;93(8):2506-2514. http://www.ncbi.nlm.nih.gov/pubmed/10194429.
9. Tassi C, Tazzari PL, Bonifazi F, et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant. 2005;36(4):289-294. doi:10.1038/sj.bmt.1705066
10. Vasu S, Leitman SF, Tisdale JF, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008;112(5):2092-2100. doi:10.1182/blood-2008-03-143677
11. Zubair AC, Grant R, Wu W, et al. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion. 2008;48(6):1106-1114. doi:10.1111/j.1537-2995.2008.01651.x
12. Suzuya H, Watanabe T, Nakagawa R, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang. 2005;89(4):229-235. doi:10.1111/j.1423-0410.2005.00701.x
13. Anderlini P, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion. 1997;37(5):507-512. doi:10.1046/j.1537-2995.1997.37597293882.x
14. Favre G, Beksaç M, Bacigalupo A, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant. 2003;32(9):873-880. doi:10.1038/sj.bmt.1704245
15. De Lavallade H, Ladaique P, Lemarié C, et al. Older age does not influence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin. Blood. 2009;113(8):1868-1869. doi:10.1182/blood-2008-11-187773
There is no Supplemental content for this article.

How to Cite This

Gokgoz, Z. (2020). Does platelet/ lymphocyte ratio a predictor of CD34+ peripheral blood stem cell yield in the healthy donors mobilized with GCSF?. Jurnal Teknologi Laboratorium, 9(1), 115–120. https://doi.org/10.29238/teknolabjournal.v9i1.209

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Verify authenticity via CrossMark

Copyright and Permissions

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

  • BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability